Eli Lilly and Company
Financials
Valuation Metrics
Eli Lilly and Company's Market Cap is $1.33T. At end of 2025 it was $963.46B. Ranked #11 of 3,116 in US market (top 0.4%), #2 of 1,644 on NYSE (top 0.1%), #1 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.33T | US#11/3,116 Sec#1/265 |
| Revenue | $86.46B | US#69/3,116 Sec#2/265 |
| Net Income | $27.58B | US#15/3,116 Sec#1/265 |
| Total Assets | $148.07B | US#131/3,116 Sec#4/265 |
| Net Assets | $40.27B | US#138/3,116 Sec#9/265 |
| Employees | 50,000 | US#254/3,116 Sec#10/265 |
| Value | ||
| P/E | 48.17x | US#1,891/3,116 Sec#53/265 |
| P/B | 32.99x | US#2,868/3,116 Sec#228/265 |
| PEG | 0.97x | US#605/3,116 Sec#21/265 |
| P/S | 15.37x | US#2,808/3,116 Sec#136/265 |
| EV/EBITDA | 30.69x | US#2,212/3,116 Sec#64/265 |
| FCF Yield | 1.48% | US#2,091/3,116 Sec#69/265 |
| Profitability | ||
| ROE | 68.49% | US#49/3,116 Sec#2/265 |
| ROA | 18.63% | US#138/3,116 Sec#21/265 |
| Op. Margin | 46.07% | US#125/3,116 Sec#6/265 |
| Revenue Growth | 45.51% | US#225/3,116 Sec#50/265 |
| Earnings Growth | 49.79% | US#312/3,116 Sec#14/265 |
| Financial Health | ||
| Debt Ratio | 267.69% | US#2,143/3,116 Sec#212/265 |
| Total Debt | $49.50B | US#80/3,116 Sec#4/265 |
| FCF | $19.66B | US#26/3,116 Sec#2/265 |
| Cash | $4.88B | US#117/3,116 Sec#3/265 |
| Current Ratio | 1.39x | US#1,822/3,116 Sec#244/265 |
| Net Debt/EBITDA | 1.00x | US#993/3,116 Sec#46/265 |
| Dividend | ||
| Div. Yield | 0.45% | US#1,549/3,116 Sec#24/265 |
| Div. Growth | 15.36% | US#331/3,116 Sec#4/265 |
| Performance | ||
| 1Y Return | 64.08% | US#315/3,116 Sec#60/265 |
| 1M Return | 23.49% | US#360/3,116 Sec#30/265 |
| From 52W High | -2.64% | US#259/3,116 Sec#23/265 |
| 1Y MDD | -23.18% | US#842/3,116 Sec#32/265 |
| Trading | ||
| Volume | 2,756,115 shares | US#523/3,116 Sec#44/265 |
| Trading Value | $3.88B | US#16/3,116 Sec#1/265 |
| Per Share | ||
| EPS | $29.30 | US#51/3,116 Sec#3/265 |
| BPS | $42.78 | US#729/3,116 Sec#13/265 |
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.